Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu; Stephen D. Schmidt; Chloe A. Talana; Jim Albert; Evan Anderson; Hamilton Bennett; Kizzmekia Corbett; Britta Flach; Lisa Jackson; Brett Leav; Julie E. Ledgerwood; Catherine J. Luke; Mat Makowski; Paul C. Roberts; Mario Roederer; Paulina Alejandra Rebolledo; Christina A. Rostad; Nadine G. Rouphael; Lingshu Wang; Eun Sung Yang; John H. Beigel; Barney S. Graham; John R. Mascola; Adrian McDermott; Nicole A Doria-Rose.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-444010

Documentos relacionados

  1. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.
  2. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
  3. Antibody evasion by the P.1 strain of SARS-CoV-2.
  4. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
  5. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
  6. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
  7. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
  8. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8<sup>+</sup> T cell responses.
  9. Memory CD8<sup>+</sup> T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
  10. Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination.